Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up

Journal of Medical Virology

Volumn 75, Issue 2, 2005, Pages 240-248

  Hiraga, Nobuhiko ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Matsuda, Marie ^a   Watabiki, Sachiko ^a   Satoh, Junko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Alanine aminotransferase; Chronic hepatitis C; Flare up; Genotype

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; CHRONIC HEPATITIS; COMPLEMENTARITY DETERMINING REGION; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; VIROLOGY; VIRUS CORE; VIRUS DETECTION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; AMINO ACID SEQUENCE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 19944429167     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20263     Document Type: Article

References (45)

1. Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2002. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: Therapy efficacy as consequence of tripartite interaction of viral, host, and interferon treatment-related factors. J Hepatol 37:831-836.
2. Akuta N, Suzuki F, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003. Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype 2a low viral load and response to interferon monotherapy. J Med Virol 69:376-383.
3. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Suzuki F, Kumada H. 2000. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 35:221-225.
4. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Suzuki F, Kumada H. 2000. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course. J Gastroenterol 35:607-612.
5. Boulestin A, Sandres-Saune K, Payen JL, Alric L, Dubois M, Pasquier C, Vinel JP, Pascal JP, Puel J, Izopet J. 2002. Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha. J Med Virol 68:221-228.
6. Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, et al. 1993. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 8:150-156.
7. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H. 1997. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745-749.
8. Chen JD, Chung JL, Kao JH, Chen DS. 2001. Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. J Gastroenterol Hepatol 16:705-708.
9. Cohen J. 1999. The scientific challenge of hepatitis C virus. Science 285:26-30
10. Desmet VJ, Gerber M, Hoofnagale JH, Manns M, Sheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 19:1513-1520.
11. Dusheiko GM. 1998. The natural course of chronic hepatitis C: Implications for clinical practice. J Viral Hepatol 5:9-12.
12. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New Engl J Med 334:77-81.
13. Fang CT, Tobler LH, Haesche C, Busch MP, Phelps B, Leparc G. 2003. Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor. Transfusion 43:541-544.
14. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. 2001. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 79:515-536.
15. Hashimoto M, Chayama K, Kobayashi M, Tsubota A, Arase Y, Saitoh S, Suzuki Y, Ikeda K, Matsuda M, Koike H, Kobayashi M, Handa H, Kumada H, Kobayashi M, Handa H, Kumada H. 1999. Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region. J Med Virol 58:247-255.
16. Hattori Y, Orito E, Ohno T, Sugauchi F, Suzuki S, Sugiura M, Suzumori K, Hattori K, Ueda R, Mizokami M. 2003. Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection. J Med Virol 71:205-211.
17. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. 1991. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 28:175:220-228.
18. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. 1998. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2,215 patients. J Hepatol 28:930-938.
19. Ina Y, Mizokami M, Ohba K, Gojobori T. 1994. Reduction of synonymous substitutions in the core protein gene of hepatitis C virus. J Mol Evol 38:50-56.
20. Kato N, Ootsuyama Y, Ohkoshi S, Nakazawa T, Sekiya H, Hijikata M, Shimotohno K. 1992. Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. Biochem Biophys Res Commun 189:119-127.
21. Kenny-Walsh E. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. New Engl J Med 22:1228-1233.
22. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. 1996. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 23:695-699.
23. Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, Ukai K, Yano M, Takagi K, Hattori M, Kakumu S, Yoshioka K. 2002. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Am J Gastroenterol 97:988-998.
24. Kuramoto IK, Moriya T, Schoening V, Holland PV. 2002. Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. J Viral Hepatol 9:36-42.
25. Liaw YF. 2003. Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 18:246-252.
26. Liaw YF, Tsai SL. 1997. Pathogenesis and clinical significance of acute exacerbations and remission in patients with chronic hepatitis B virus infection. Viral Hepatol Rev 3:143-154.
27. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. 1999. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30:1045-1053.
28. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D. 1998. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 28:1687-1695.
29. Otsuka M, Kato N, Lan K, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M. 2000 Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 275:34122-34130.
30. Patel T, Steer CJ, Gores GJ. 1999. Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. Hepatology 30:811-815.
31. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. 2000. Standardization of hepatitis C virus RNA quantification. Hepatology 32:654-659.
32. Pontisso P, Bellati G, Brunetto M, Chemello L, Colloredo G, Di Stefano R, Nicoletti M, Rumi MG, Ruvoletto MG, Soffredini R, Valenza LM, Colucci G. 1999. Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity? Hepatology 29:585-589.
33. Ray RB, Ray R. 2001. Hepatitis C virus core protein: Intriguing properties and functional relevance. FEMS Microbiol Lett 202:149-156.
34. Rumi MG, De Filippi F, Donato MF, Del Ninno E, Colombo M. 2002. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepatol 9:71-74.
35. Saito S, Kato N, Hijikata M, Gunji T, Itabashi M, Kondo M, Tanaka K, Shimotohno K. 1996. Comparison of hypervariable regions (HVR1 and HVR2) in positive- and negative-stranded hepatitis C virus RNA in cancerous and non-cancerous liver tissue, peripheral blood mononuclear cells and serum from a patient with hepatocellular carcinoma. Int J Cancer 67:199-203.
36. Sherman KE. 1991. Alanine aminotransferase in clinical practice. A review. Arch Intern Med 151:260-265.
37. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti B, Civardi E, Salvaneschi L. 1995. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 21:285-290.
38. Simmonds P. 1995. Variability of hepatitis C virus. Hepatology 21:570-583.
39. Terazawa Y, Yoshioka K, Kobayashi M, Watanabe K, Ishigami M, Yano M, Takagi K, Kakumu S. 2000. Mutations in interferon sensitivity-determining region of hepatitis C virus: Its relation to change in viral load. Am J Gastroenterol 95:1781-1787.
40. Tokita H, Okamoto H, Tsuda F, Song P, Nakata S, Chosa T, Iizuka H, Mishiro S, Miyakawa Y, Mayumi M. 1994. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci USA 91:11022-11026.
41. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. 1994. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088-1094.
42. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M. 2001. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 183:1195-1203.
43. Watanabe H, Saito T, Shinzawa H, Okumoto K, Hattori E, Adachi T, Takeda T, Sugahara K, Ito JI, Saito K, Togashi H, Suzuki R, Hayashi M, Miyamura T, Matsuura Y, Kawata S. 2003. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study. J Med Virol 71:56-61.
44. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc Natl Acad Sci USA 89:3468-3472.
45. Yoshioka K, Aiyama T, Okumura A, Takayanagi M, Iwata K, Ishikawa T, Nagai Y, Kakumu S. 1997. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J Infect Dis 175:505-510.